Regulus Therapeutics Inc (NASDAQ:RGLS)

0.216
Delayed Data
As of Jan 27
 +0.0009 / +0.42%
Today’s Change
0.19
Today|||52-Week Range
2.32
-31.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$19.5M

Company Description

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.

Contact Information

Regulus Therapeutics, Inc.
4224 Campus Point Court
San Diego California 92121
P:(858) 202-6300
Investor Relations:
(858) 202-6376

Employees

Shareholders

Mutual fund holders9.43%
Other institutional7.25%
Individual stakeholders10.66%

Top Executives

Joseph P. HaganPresident, Chief Executive Officer & Director
Crispina CalsadaChief Financial Officer
Denis DryginChief Scientific Officer
Christopher AkerSecretary, Senior Vice President & General Counsel
Daniel PenksaChief Accounting Officer & Controller